Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03624699
Other study ID # GLK-iStent-inject
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 25, 2018
Est. completion date June 30, 2020

Study information

Verified date May 2022
Source Swiss Vision Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the safety and intraocular pressure (IOP) lowering effect of two iStent inject devices in combination with cataract surgery in patients with mild-to-moderate open-angle glaucoma.


Description:

Patients suffering from open-angle glaucoma who are planning to undergo cataract surgery and are matching the inclusion criteria will be offered to join the study until the desired sample size (50) is reached. Combined cataract-iStent surgery will be performed as per the devices' manufacturers' instructions. Two iStent inject devices will be micro-invasively implanted in the trabecular meshwork of the eye during planned cataract surgery. Six post-operative follow-ups will be carried out over a duration of 12 months, during which various measurements will be made. Performance Outcomes will analyse the proportion of patients with IOP reduction of ≥ 20% vs. baseline mean IOP, at 6 and 12 months. Quality of life outcome will look at the improvement in perceived quality of life as expressed in the NEI VFQ-25 questionnaires from baseline to 3 and 12 months. The rate of adverse events will be recorded.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date June 30, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma - Mild to moderate glaucoma (defined as C/D ratio = 0.8) - Phakic eye requiring cataract surgery - Preoperative IOP up to 30 mmHg (medicated or not) - Patients with side-effects to, or complications from, medications - Patients who would benefit from a reduction of IOP and/or reduction of medication - Normal angle anatomy as determined by gonioscopy; - Absence of peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities that could impair proper placement of iStent inject device - Able and willing to attend scheduled follow-up exams for 12 months postoperatively - Able and willing to provide written informed consent on the approved Informed Consent Form Exclusion Criteria: - Inclusion of the fellow eye in this study (only one eye per subject) - Aphakic patients or pseudophakic patients - Prior stent implantations in the study eye - Eyes with primary angle closure glaucoma, or any secondary angle closure glaucoma - Traumatic or uveitic glaucoma; or any glaucoma associated with vascular disorders - Patients with any type of condition that may cause elevated episcleral venous pressure - Functionally significant visual field loss, including severe nerve fiber bundle defects such as Bjerrum scotoma - Prior glaucoma treatment (laser or surgery) - Any active corneal inflammation, edema, or opacity severe-enough to impair gonioscopy / fundus examination - Any pathology for which, in the investigator's judgment, the following would be either at risk or contraindicated: - stent implantation, - compliance to elements of the study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Glaukos iStent inject®
iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma

Locations

Country Name City State
Switzerland Glaucoma Research Centre, Montchoisi Clinic Lausanne VD

Sponsors (2)

Lead Sponsor Collaborator
Dr. Kaweh Mansouri Glaukos Corporation

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance Outcome: IOP reduction Proportion of patients with IOP reduction of = 20% vs. baseline mean IOP, at 12 months. 12 months
Secondary Quality of life: NEI VFQ-25 score Improvement in perceived quality of life as expressed in the NEI VFQ-25 (National Eye Institute Vision Function) questionnaires from baseline to 12 months. 12 months
Secondary Safety Outcome: Adverse events Rate of adverse events through the follow-up period. 12 months
See also
  Status Clinical Trial Phase
Completed NCT05044793 - A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
Recruiting NCT06201455 - Evaluation of Phacogoniotomy in Medically-controlled POAG N/A
Recruiting NCT03369886 - The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI N/A
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Recruiting NCT02679482 - Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma N/A
Completed NCT02338362 - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma Phase 4
Active, not recruiting NCT01430923 - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost N/A
Completed NCT01489670 - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension N/A
Completed NCT00693485 - Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy Phase 2
Completed NCT00753168 - Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Phase 1/Phase 2
Completed NCT00051194 - A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension Phase 2
Recruiting NCT04920227 - Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma N/A
Active, not recruiting NCT03868124 - Clinical Study Comparing Two Models of a Travoprost Intraocular Implant Phase 3
Completed NCT03267862 - Scleral Response to Intraocular Pressure (IOP) N/A
Recruiting NCT06066645 - Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone Phase 3
Recruiting NCT04912362 - The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma N/A
Completed NCT04949802 - Glaucoma Surgery Using the ViaLase Laser System N/A
Recruiting NCT04038034 - Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma N/A
Completed NCT04632329 - Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma N/A
Completed NCT01215786 - Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Phase 1